Compare LTC Properties Inc (LTC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Sanofi SA — how do they compare? LTC Properties Inc trades at $42.5 (market cap $2.15B), while Sanofi SA trades at $44.02 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 48.8× LTC Properties Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| LTC | SNY | |
|---|---|---|
Market Cap | $2.15B | $104.83B |
Sector | Real Estate | Health |
52-Week High | $41.92 | $52.34 |
52-Week Low | $33.98 | $41.33 |
Enterprise Value | $2.99B | $121.32B |
Dividend Yield | 5.44% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $41.92, up 0.41% with a bullish technical outlook. The REIT shows strong fundamentals with 2025 revenue of $263M and net income of $118M, supported by a 67.3% gross margin. Recent acquisitions expand its SHOP portfolio, targeting demographic trends in senior housing. Analyst sentiment is mixed with 27% buy ratings amid recent earnings misses.
Outlook: Growth driven by strategic acquisitions and aging demographics, but execution risks and debt levels warrant caution. Near-term focus on Q2 2026 earnings (expected EPS $0.48) as a key catalyst. Dividend yield of ~5.4% provides income appeal.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
